Seattle, Washington
March 4–7, 2019


Conference Dates and Location: 
March 3-6, 2014 | Boston, Massachusetts
Abstract Number: 

Modeling the Performance and Cost of Early Infant HIV Diagnosis at Birth


Intira J. Collins, Martina Penazzato, Dick Chamla, Anisa Ghadrshenas, Teri Roberts, Jennifer Cohn, Nicole Ngo-Giang-Huong, Nathan Shaffer, Meg Doherty, Lisa J. Nelson *MRC Clinical Trials Unit, London, United Kingdom, HIV Department, World Health Organization, Geneva, Switzerland, UNICEF, New York, NY, United States, Clinton Health Access Initiative, Nairobi, Kenya, Medecins sans Frontieres, Geneva, Switzerland, Programs for HIV Prevention and Treatment (IRD-PHPT), Chiang Mai, Thailand

Abstract Body: 

Background: Untreated HIV-infected infants are at high risk of death in the first year of life. WHO recommends early infant diagnosis (EID) using virological testing (VT) from 6 weeks, but coverage is poor. Testing at birth (BT) was hypothesized to improve EID coverage and reduce mortality by earlier initiation of ART, although VT has poorer sensitivity at birth. We modelled the performance and cost of BT against the current WHO algorithm. We present preliminary results of the model applied to South Africa. Methodology: A decision tree cohort simulation model was developed and applied to infants born in a prevention of mother to child transmission of HIV (PMTCT) program setting. Infants enter the model at birth with a risk of in-utero, intra- and post-partum transmission. In the BT algorithm, children are tested at birth (0-3 days), 12 wks, 9 and 18 months vs. testing at 6 wks, 9 and 18 months in the WHO algorithm. Both algorithms include testing at end of breastfeeding. The model runs up to 24 months of age. HIV-infected children have a probability of diagnosis, referral for HIV care, ART initiation or pre-ART death (Table 1). Outcomes of interest were positive predictive value (PPV), negative predictive value (NPV) of VT, cost per diagnosis, proportion of HIVinfected children correctly diagnosed, initiated on ART and pre-ART deaths. Results: PPV and NPV was 88.5% and 97.6% in BT and 90.8% and 97.6% in the WHO algorithm, respectively. Cost per HIV-infected diagnosis was $1,379 and $458, respectively. The proportion of HIV-infected children diagnosed by 24 months was 69.2% in BT vs 54.9% in WHO algorithm. However, the proportion of HIV-infected children starting ART was more comparable at 37.0% vs 32.4%; and pre-ART deaths was 24.9% vs 26.7% respectively. In scenario analyses, assuming improved EID coverage, retention and referral for ART (90%) the proportion starting ART rose to 70.2% vs. 68.5%, and pre-ART deaths fell to 17.1% and 18.1% respectively. In contrast, if we assumed current coverage/referral rates but higher sensitivity of BT (98%), the proportion of HIV-infected diagnosed rose to 75.2%, but with modest improvements in proportions starting ART(40.7%) and pre-ART death (23.1%). Conclusions: EID at birth would potentially increase the proportion of HIV-infected children diagnosed, but has lower PPV; if not accompanied by improved retention and referral for ART, it offers limited improvements in proportion starting ART or in reducing pre-ART mortality.

Session Number: 
Session Title: 
Early Infant HIV Diagnosis